XTL Biopharma to Acquire AI Web Data Firm Social Proxy
Ticker: XTLB · Form: 6-K · Filed: Mar 20, 2024 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Mar 20, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $430,000, $1,500,000, $1.20 |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, ai, data-extraction, strategic-pivot
TL;DR
XTL Biopharma buying AI data company Social Proxy - big pivot!
AI Summary
On March 20, 2024, XTL Biopharmaceuticals Ltd. announced it has entered into a binding term sheet with THE SOCIAL PROXY Ltd., an AI web data company. This agreement involves XTL Biopharmaceuticals Ltd. acquiring Social Proxy.
Why It Matters
This acquisition signals XTL Biopharmaceuticals' strategic move into the AI and data extraction sector, potentially diversifying its business beyond traditional biopharmaceuticals.
Risk Assessment
Risk Level: medium — The acquisition of a company in a different sector introduces integration and market execution risks for XTL Biopharmaceuticals.
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — Acquiring company
- THE SOCIAL PROXY Ltd. (company) — Target company
- March 20, 2024 (date) — Announcement date
FAQ
What is the primary business of THE SOCIAL PROXY Ltd.?
THE SOCIAL PROXY Ltd. is an AI web data company that develops and powers an ethical, IP-based proxy and data extraction platform for AI & BI Applications at scale.
What is the nature of the agreement between XTL Biopharmaceuticals Ltd. and THE SOCIAL PROXY Ltd.?
XTL Biopharmaceuticals Ltd. has entered into a binding term sheet with THE SOCIAL PROXY Ltd., indicating an acquisition.
When was this agreement announced?
The announcement was made on March 20, 2024.
What is the filing form used for this announcement?
The filing form used is a 6-K Report of Foreign Private Issuer.
Where is XTL Biopharmaceuticals Ltd. based?
XTL Biopharmaceuticals Ltd. is based in Ramat Gan, Israel.
Filing Stats: 1,274 words · 5 min read · ~4 pages · Grade level 15.8 · Accepted 2024-03-20 10:15:45
Key Financial Figures
- $430,000 — tal of the Company and the payment of US$430,000 to the shareholders of the Social Proxy
- $1,500,000 — ment of an investment of an amount of US$1,500,000 through a private placement to be consu
- $1.20 — into one ADS at an exercise price of US$1.20 per warrant. The Investment is conditio
Filing Documents
- ea0202193-6k_xtlbiopharma.htm (6-K) — 21KB
- ea020219301ex99-1_xtlbio.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-024228.txt ( ) — 42KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: March 20, 2024 XTL BIOPHARMACEUTICALS LTD. By: /s/ Shlomo Shalev Shlomo Shalev Chief Executive Officer 3